Muhammed Cihan Işık

Muhammed Cihan Işık

Auto-generated profile, based on publicly available information

Muhammed Cihan Işık

Hacettepe University

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2025 in International Journal of Antimicrobial Agents
Verified
Journal Article
Open access
AAAbdullah Tarik Aslan
Abdullah Tarik Aslan
ETElif Seren Tanriverdi
Elif Seren Tanriverdi
SKSibel Yıldız Kaya
Sibel Yıldız Kaya
GDGozde Dalgan
Gozde Dalgan
NSNeşe Saltoğlu
Neşe Saltoğlu
Murat AkovaMurat Akova
Murat Akova
Due to underrepresentation of carbapenemase-producing Enterobacterales infections in randomized controlled trials with ceftazidime-avibactam (CZA) and high cost of CZA therapy, other appropriate antimicrobial therapies (OAAT) are still being used for OXA-48- or KPC-producing Enterobacterales infections in Türkiye. We conducted a multicentre retrospective 1:1 matched cohort study of patients who received ≥48 h of CZA or OAAT for documented OXA-48- or KPC-producing Enterobacterales infections. Patients were matched based on (1) the number of days (± 1 d) from the infection onset to the initiation of therapy, (2) INCREMENT-CPE score (± 1), (3) source of infection, (4) year of infectious episode, and (5) type of causative microorganism. From 5 Turkish university hospitals, 180 patients were enrolled. Baseline characteristics were all similar between treatment groups. At the time of treatment initiation, 63.9% of patients were in the intensive care unit, 35.6% had septic shock and 41.1% required mechanical ventilation support. Thirty-day mortality occurred in 35.6% (32/90) of patients treated with CZA and in 56.7% (51/90) of those receiving OAAT regimens (P = 0.004). Twenty-one-day clinical response was seen in 50% (45/90) and 26.7% (24/90) of patients receiving CZA and OAAT, respectively (P = 0.002). In multivariable logistic regression analyses, CZA treatment was associated with less likelihood of mortality (aOR = 0.37; 95% CI: 0.19-0.71; P = 0.003) and higher likelihood of 21-d clinical response (aOR = 3.32; 95% CI: 1.68-6.53; P < 0·001). Treatment with CZA is associated with more favourable clinical outcomes in treatment of OXA-48- or KPC-producing Enterobacterales infections. A randomized controlled trial is needed to confirm these results.

24 June 2026 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Open access
EKEkin Kırbaş
Ekin Kırbaş
MIMuhammed Cihan Işık
Muhammed Cihan Işık
RIRashad Ismayilov
Rashad Ismayilov
SUSerhat Unal
Serhat Unal
BSBanu Sancak
Banu Sancak
Purpose: Carbapenem-resistant Pseudomonas aeruginosa (CRPA) has been classified by the World Health Organization as one of the most alarming antimicrobial-resistant microorganisms. Despite the availability of newer therapeutic options, polymyxins remain important last-resort agents for the treatment of CRPA infections in many settings. With the extended use of polymyxins in the treatment of extensively drug-resistant bacterial infections, both colistin resistance rates, colistin heteroresistance (CHR) rates and antibiotic treatment failures have risen. In this study, we aimed to: (i) determine the prevalence of CHR in P. aeruginosa bloodstream isolates, (ii) compare the accuracy of the antibiotic gradient test (GT) with the population analysis profiling (PAP) method, and (iii) identify clinical risk factors for CHR. Methods: CHR was investigated among 70 colistin-susceptible P. aeruginosa strains isolated from blood cultures using PAP and GT methods. Clinical and demographical data were retrospectively reviewed, and risk factors for CHR were analyzed using logistic regression. Results: We detected a remarkably high prevalence of CHR (61.4%) among colistin-susceptible P. aeruginosa bloodstream isolates. The gradient test failed to detect any of the heteroresistant strains. Our analysis revealed that age ≥ 60 years, lack of recent hospitalization, and a colistin MIC of 1 mg/L, compared with 2 mg/L, were independently associated with an increased risk of CHR. CHR was not significantly associated with 30-day or 90-day mortality. Conclusion: Despite the microbiological importance of heteroresistance, the clinical impacts and underlying mechanisms of this phenotype remain to be elucidated.

12 September 2022 in Flora the Journal of Infectious Diseases and Clinical Microbiology
Verified
Journal Article
Closed access
MIMuhammed Cihan Işık
Muhammed Cihan Işık
PZPinar Zarakolu
Pinar Zarakolu

28 July 2026 in Infectious Diseases and Clinical Microbiology
Verified
Journal Article
Open access
NANagihan Aka
Nagihan Aka
MIMuhammed Cihan Işık
Muhammed Cihan Işık
TPTuğba Pamukçu
Tuğba Pamukçu
GTGülçin Telli-Dizman
Gülçin Telli-Dizman
ABAli Batur
Ali Batur
Murat AkovaMurat Akova
Murat Akova
Objective: Wound infections represent a major concern among earthquake survivors. Antibacterial prophylaxis is standard care for this population. However, there is no clear consensus guidelines regarding the choice of prophylactic agents. This study aimed to examine whether the spectrum of antibacterial prophylaxis affects wound infection rates in hospitalized survivors of the February 2023 earthquake in south-eastern Türkiye who were transferred to a tertiary care center outside the disaster zone. Materials and Methods: This retrospective study included patients with uninfected wounds upon hospital admission. Clinical characteristics, prophylaxis regimens, and microbiological data were analyzed to identify factors associated with subsequent infection. Results: The study included 83 patients. Post-admission wound infections developed in 13 patients (15.6%). These patients were more likely to require intensive care unit (ICU) admission, hemodialysis, and recurrent surgeries than those without infections. Notably, infected patients had received broader-spectrum prophylaxis (84.6% vs. 31.4%, p < 0.001), yet wound contamination with soil or debris was not significantly different between groups. Multivariable analysis identified ICU requirement as an independent risk factor for infection (adjusted odds ratio [aOR] 44.81; 95% confidence interval [CI] 6.55–306.51; p < 0.001), while prior antibiotic exposure before admission was associated with a lower risk of infection (aOR 0.10; 95% CI 0.01–0.69; p = 0.019). Among isolated bacteria, 76.5% were either extensively drug-resistant or multidrug-resistant, with Acinetobacter baumannii and Klebsiella pneumoniae being the predominant pathogens. Conclusion: The findings suggest that broad-spectrum prophylaxis alone is insufficient to prevent infections caused by highly resistant pathogens in disaster settings. The study highlights the critical need for strict adherence to infection prevention and control (IPC) measures. Overwhelming patient burden can diminish compliance with IPC practices and lead to prophylaxis failure. To manage difficult-to-treat infections, it is vital to implement additional protocols that ensure IPC integrity even under extreme workload conditions.

4 March 2024 in Research Square
Verified
Preprint
Open access
PDF file
MIMuhammed Cihan Işık
Muhammed Cihan Işık
GMGökhan Metan
Gökhan Metan
AAAlpaslan Alp
Alpaslan Alp
DGDolunay Gülmez
Dolunay Gülmez
SASevtap Arikan-Akdagli
Sevtap Arikan-Akdagli
ÖUÖmrüm Uzun
Ömrüm Uzun
The authors have requested that this preprint be removed from Research Square.

29 May 2026 in Acta Microbiologica Et Immunologica Hungarica
Verified
Journal Article
Closed access
MIMuhammed Cihan Işık
Muhammed Cihan Işık
GDGülçin Telli Dizman
Gülçin Telli Dizman
NGNur Dilek Gül
Nur Dilek Gül
IDİlKnur Tekin Demir
İlKnur Tekin Demir
HAHanife Aytaç Ak
Hanife Aytaç Ak
GMGökhan Metan
Gökhan Metan
Lack of standardized criteria for discontinuing contact precautions (CP) in patients colonized or infected with multidrug-resistant bacteria (MDRB) can prolong isolation and strain healthcare resources. This retrospective cohort study aimed to assess the safety of a protocol-guided CP discontinuation strategy and identify risk factors for MDRB reacquisition. The study evaluated 88 adult patients under CP who met an institutional protocol for CP discontinuation between 2018 and 2023. The protocol required: no active infection; no antibiotic use in the preceding seven days; no drains or open wounds; no diarrhea; a negative culture from the initial site of MDRB identification; and a subsequent confirmatory negative screening (culture and/or PCR). Patients were followed for one year after CP discontinuation to assess MDRB reacquisition, defined as a new positive specimen for the same species. Potential risk factors for reacquisition were analyzed using multivariable Cox regression. At the one-year follow-up, MDRB reacquisition occurred in 17% (15/88) of patients. The reacquired pathogens included carbapenem-resistant Enterobacterales (9/50), methicillin-resistant Staphylococcus aureus (6/30), and vancomycin-resistant Enterococcus spp. (0/8). Independent risk factors for reacquisition were chronic obstructive pulmonary disease (HR 5.76, 95% CI 1.34–24.81), shorter duration of isolation (HR 0.98 per day, 95% CI 0.97–0.99), frequent hospitalizations (HR 1.75 per admission, 95% CI 1.07–2.88), and central venous catheterization (HR 13.04, 95% CI 2.63–64.69). Protocol-guided CP discontinuation was associated with a low rate of MDRB reacquisition and appears safe in appropriately selected patients. This approach may reduce unnecessary isolation in eligible patients, though high-risk individuals require closer monitoring.